1194-06-5

Basic information

• Product Name: CYCLOPENTYL-UREA
• Synonyms: 1-Cyclopentylurea;N-Cyclopentylurea;1-Cyclopentylurea（WS202893）
• CAS NO: 1194-06-5
• Molecular Formula: C6H12N2O
• Molecular Weight: 128.1723
• Mol File: 1194-06-5.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 220.3°Cat760mmHg
• Flash Point: 87°C
• Appearance: /
• Density: 1.08g/cm³
• Vapor Pressure: 0.114mmHg at 25°C
• Refractive Index: 1.504
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: CYCLOPENTYL-UREA(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOPENTYL-UREA(1194-06-5)
• EPA Substance Registry System: CYCLOPENTYL-UREA(1194-06-5)

Safety Data

• Hazardous Substances Data: 1194-06-5(Hazardous Substances Data)

Usage

General Description

Cyclopentyl-Urea is a chemical compound that belongs to the class of organic compounds known as dialkylureas. It is defined as a urea that is urea in which the amino groups are substituted by cyclopentyl groups. They contain a urea moiety with two cyclopentyl groups attached to it. This chemical is not commonly found, however, it can be used in the manufacturing of pharmaceuticals and as an intermediate in organic synthesis. The safety, toxicity, and environmental impact of Cyclopentyl-Urea may vary depending on the specific applications and uses. Like with any chemical substances, appropriate handling and management are needed to ensure safety.

InChI:InChI=1/C6H12N2O/c7-6(9)8-5-3-1-2-4-5/h5H,1-4H2,(H3,7,8,9)

Upstream product

• 1118-02-1 trimethylsilyl isocyanate 
• 1003-03-8 Cyclopentamine 
• 142-29-0 cyclopentene 
• 57-13-6 urea 

Relevant articles and documents

Nitrogenous condensed heterocyclic compound as well as preparation method, intermediate, composition and application thereof

The invention discloses a nitrogenous condensed heterocyclic compound as well as a preparation method, an intermediate, a composition and application thereof. The compound disclosed by the invention has high inhibition activity for different subtypes of CDK (Cyclin-Dependent Kinase) at a molecular level, has good inhibition activity on breast cancer cells at a cell level, has a remarkable proliferation inhibition function on tumor cells related to cyclin-dependent kinase activity at an animal level, is good in liver microsome stability upon human beings, mice, and the like, is good in in-vivoabsorption in mice and rats, is high in bioavailability and is good in druggability.

Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia

A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.